---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-104144"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:41:19.420142+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IN8bio reports FY2025 net loss $19.4M; GBM trial shows 97% PFS improvement

## Summary
- Net loss $19.4M ($4.44/share) vs $30.4M ($17.05/share) prior year; cash $27.1M vs $11.1M year-end 2024.
- Updated GBM data: mPFS 13.0 months for DRI patients vs 6.6 months SOC (+97%); mOS not yet reached at 17.2+ months.
- Closed initial $20.1M of $40.2M private placement; net proceeds $18.5M extend cash runway into H1 2027.
- Kate Rochlin promoted to President and COO in February 2026.
- Anticipates FDA guidance on regulatory pathway for GBM program by H2 2026.

## SEC filing metadata
- accession: 0001193125-26-104144
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312526104144/0001193125-26-104144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312526104144/inab-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-104144
- JSON: https://secwatch.observer/filing/0001193125-26-104144.json
- Plain text: https://secwatch.observer/filing/0001193125-26-104144.txt

## Key facts
- Earnings Releases
  IN8BIO, INC. reported financial results for fourth quarter and fiscal year ended December 31, 2025.
  - Period: fourth quarter and fiscal year ended December 31, 2025
  - Result: reported results
  source text: On March 12, 2026, IN8bio, Inc. (the “Company”) issued a press release announcing its financial results for fourth quarter and fiscal year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1740279/000119312526104144/0001193125-26-104144-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.